Sarepta Therapeutics (SRPT) Net Cash Flow (2010 - 2026)

Sarepta Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$336.8 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 60.93% year-over-year to -$336.8 million; the TTM figure through Mar 2026 stood at $221.1 million (up 218.62% YoY), while the FY2025 annual figure was -$304.2 million, down 145.09% from the prior year.
• Net Cash Flow was -$336.8 million for Q1 2026 at Sarepta Therapeutics, down from $188.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $905.2 million in Q4 2024 to a low of -$882.0 million in Q1 2022.
• Historically, Net Cash Flow has averaged -$96.9 million across 5 years, with a median of -$71.8 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow surged 873.16% in 2024, then sank 75526.58% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$71.8 million in 2022, then sank by 62.95% to -$117.1 million in 2023, then soared by 873.16% to $905.2 million in 2024, then plunged by 79.21% to $188.2 million in 2025, then tumbled by 278.97% to -$336.8 million in 2026.
• The last three Net Cash Flow figures came in at -$336.8 million (Q1 2026), $188.2 million (Q4 2025), and $100.0 million (Q3 2025), per Business Quant data.